Obeticholic Acid: A New Era in the Treatment of Nonalcoholic Fatty Liver Disease
The main treatments for patients with nonalcoholic fatty liver disease (NAFLD) are currently based on lifestyle changes, including ponderal decrease and dietary management. However, a subgroup of patients with nonalcoholic steatohepatitis (NASH), who are unable to modify their lifestyle successfully...
Saved in:
Main Authors: | Ludovico Abenavoli (Author), Tetyana Falalyeyeva (Author), Luigi Boccuto (Author), Olena Tsyryuk (Author), Nazarii Kobyliak (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2018-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Combined obeticholic acid and apoptosis inhibitor treatment alleviates liver fibrosis
by: Jiyu Zhou, et al.
Published: (2019) -
Nonalcoholic fatty liver disease: New epidemic
by: Rajkumar P Wadhwa, et al.
Published: (2021) -
The protective effect and mechanism of the FXR agonist obeticholic acid via targeting gut microbiota in non-alcoholic fatty liver disease
by: Zhang DY, et al.
Published: (2019) -
Semaglutide in the treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
by: Magdalena Mazurek, et al.
Published: (2023) -
Role of Bile Acids in Dysbiosis and Treatment of Nonalcoholic Fatty Liver Disease
by: Caihua Wang, et al.
Published: (2019)